Two ongoing, multicenter, promising trials of PAK4 inhibitors are testing the safety of the orally bioavailable dual inhibitors ATG-019 and KPT-9274, targeting the PAK4 and PAK4 and NAMPT in advanced solid tumors, in non-Hodgkin’s lymphoma [123], and in relapsed acute myeloid leukemia [124]. Here, PAK4 is linked to non-Hodgkin lymphoma.